BioIVT acquires PrecisionMed for neurology and oncology research
BioIVT has announced that it has acquired PrecisionMed, a leading supplier of high-quality human biological material for genetics, drug discovery and biomarker research as well as in vitro diagnostics. BioIVT is a research partner and biospecimen solutions provider with a focus on drug and diagnostics development.
PrecisionMed is based in California, US, and has been collecting biospecimens for both neurology and oncology for over 27 years, comprising the largest private, global repository of longitudinally collected human cerebrospinal fluid (CSF) samples for scientific research. The collection contains a selection of both normal and diseased CSF along with other biofluids including plasma, sera and whole blood.
Richard Haigh, PhD, BioIVT’s chief executive officer, commented: “We are thrilled to announce BioIVT’s acquisition of PrecisionMed. Our vision is to lead the biospecimen industry through expertise and innovation and our acquisition of PrecisionMed pushes us even closer to this goal. We are excited about the possibilities that lie ahead as we expand our supply network and inventory, and strengthen our capacity to meet the increasing customer demand for CSF and liquid biopsy products. Together, we will drive even greater value for our customers and further our mission of enabling smarter science.”
Eric Leach, PrecisionMed’s chief executive officer, added: “The vision at PrecisionMed has always been centered around positively impacting patients’ lives through fueling innovation and scientific discovery. We have long viewed BioIVT as the gold standard in our industry with the track record and global reach to back that up. This partnership magnifies our collective ability to reach the research community and impact patients lives. We are proud to pair our talent and resources with the world-class team at BioIVT.” Betsy Goodfellow
The US Food and Drug Administration (FDA) has granted de novo marketing authorisation to the …
Kura Oncology has shared positive preclinical data which supports the development of its next-generation farnesyl …